Pathogenesis—importance of IDH1 mutations as new markers of favourable prognosis.
Treatment—(1) brain metastases—focal treatments (e.g. neurosurgery or stereotactic radiosurgery) for patients with 1 to 3 metastases and good performance status; (2) technological advances—use of ‘cyberknife’ radiotherapy; (3) chemotherapy—use of temozolomide in combination with radiotherapy.
Oxford Medicine requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us.